Targeting phosphatidylserine for tumor cell suppression [RNA-seq]
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × KYSE30 cells, DMSO, 48h, vs 3 × KYSE30 cells, PTDSS1i, 100 nM 48h, vs 3 × U138MG cells, DMSO, 48h, vs 3 × U138MG cells, PTDSS1i, 100 nM 48h,Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting Phosphatidylserine Synthesis for Tumor Cell Suppression in Esophageal Squamous Cell Carcinoma and GlioblastomaInternational journal of molecular sciences · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE329207_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1458133 and SRA study SRP695259. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9699259 KYSE30 cells, DMSO, 48h, rep1 KYSE30 cells, DMSO, 48h,
- GSM9699260 KYSE30 cells, DMSO, 48h, rep2 KYSE30 cells, DMSO, 48h,
- GSM9699261 KYSE30 cells, DMSO, 48h, rep3 KYSE30 cells, DMSO, 48h,
- GSM9699262 KYSE30 cells, PTDSS1i, 100 nM 48h, rep1 KYSE30 cells, PTDSS1i, …
- GSM9699263 KYSE30 cells, PTDSS1i, 100 nM 48h, rep2 KYSE30 cells, PTDSS1i, …
- GSM9699264 KYSE30 cells, PTDSS1i, 100 nM 48h, rep3 KYSE30 cells, PTDSS1i, …
- GSM9699265 U138MG cells, DMSO, 48h, rep1 U138MG cells, DMSO, 48h,
- GSM9699266 U138MG cells, DMSO, 48h, rep2 U138MG cells, DMSO, 48h,
- GSM9699267 U138MG cells, DMSO, 48h, rep3 U138MG cells, DMSO, 48h,
- GSM9699268 U138MG cells, PTDSS1i, 100 nM 48h, rep1 U138MG cells, PTDSS1i, …
- GSM9699269 U138MG cells, PTDSS1i, 100 nM 48h, rep2 U138MG cells, PTDSS1i, …
- GSM9699270 U138MG cells, PTDSS1i, 100 nM 48h, rep3 U138MG cells, PTDSS1i, …
- GSE222556 Neoadjuvant PARPi or Chemotherapy in Ovarian Cancer Informs Targeting Effector Treg Cells for Homologous-Recombination-Deficient Tumors [10x scRNA-seq] 67 samples shares targeting, rna-seq
- GSE279750 ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis [RNA-seq, anti-PD-L1 therapy] 10 samples shares suppression, rna-seq
- GSE202069 RNA-seq data for tumor and adjacent non-tumor tissues from hepatocellular carcinoma patients with anti-PD-1 therapy 66 samples shares rna-seq
- GSE319641 RNA-Seq profiling of pre- and on-treatment tumor samples from breast cancer patients enrolled in the NeoTRIP trial. 401 samples shares rna-seq
- GSE205154 Bulk RNA-Seq gene expression data for 289 primary and metastatic pancreatic ductal adenocarcinoma (PDAC) tumor samples from FFPE blocks. 289 samples shares rna-seq
- GSE309595 Longitudinal Analysis of Multiple Myeloma: Therapeutic Response and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity [scRNA-seq] 270 samples shares rna-seq
- GSE297742 Bulk RNA-seq of primary tumor biopsy samples from prostate adenocarcinoma patients 234 samples shares rna-seq
- GSE294272 Tumor-resident T cells and dendritic cells form an in situ archetype for immunotherapy response in melanoma [bulk RNA-seq] 29 samples shares rna-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.